Abstract
Background/Aims
We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods
A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results
In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions
TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223).
Keywords: Helicobacter pylori, Potassium-competitive acid blocker, Tegoprazan
INTRODUCTION
Helicobacter pylori has infected nearly 50% of the world’s population;1 many studies have reported this organism as a major pathological factor in chronic gastritis and stomach cancer since it was first identified in 1983.2,3 In 1994, the International Agency for Research on Cancer of the World Health Organization classified H. pylori as a definitive carcinogen.4 H. pylori eradication is indicated for the treatment of peptic ulcer and gastric mucosa-associated lymphoid-type lymphoma and prevention of metachronous gastric cancer recurrence after endoscopic resection.5 Increasing evidence suggests that H. pylori eradication helps prevent gastric cancer, and the revised guidelines of the Kyoto global consensus report and Maastricht V/Florence consensus report led to the expansion of therapeutic targets for H. pylori eradication.6,7 These new guidelines6,7 recommended that all H. pylori infections should be eradicated, with a few exceptions.
Most of the anti-H. pylori treatment regimens include proton pump inhibitors (PPIs), to maximize the effectiveness of antibiotics through maintaining a gastric lumen pH ≥6.8 The increased intragastric pH preserves the stable conformation of antibiotics, resulting in increased antibiotic levels in gastric juice and decreased minimum inhibitory concentrations (MICs).9
Despite the combined administration of PPIs and the combination of several antibiotics, treating H. pylori infection is becoming a challenge; mainly because of antibiotic resistance.10 The rapid metabolism of PPI also contributes to the eradication failure to some extent. Therefore, a strategy focused on increasing the gastric pH using high-dose or potent PPIs can be one of the strategies to overcome the eradication failure.
Although the recommended first-line regimen was revised according to the increase in antibiotic resistance, a 7-day triple regimen comprising a PPI, amoxicillin, and clarithromycin is still widely prescribed first-line therapeutic option globally, including in Korea.5
Tegoprazan (trade name: K-CAB 50 mg tablet), a potassium-competitive acid blocker (P-CAB), was developed and launched by HK inno.N Corp. (Seoul, Korea) for the treatment of gastroesophageal reflux disease, gastric ulcer, and H. pylori eradication in 2018.11 P-CABs, such as vonoprazan, exhibit competitive binding to the potassium-binding site of H+/K+-ATPase pumps on parietal cells without activation by gastric acid. P-CABs can inhibit both active and inactive H+/K+-ATPases. P-CABs are less dependent on cytochrome P450 (CYP) 2C19. These characteristics of P-CABs make them have faster, stronger and longer action compared to PPIs.12,13 The combination of 100 mg of tegoprazan with amoxicillin and clarithromycin twice a day for 7 days maintained the intragastric pH at ≥6 for ≥20 hours from the first day,14 which was equivalent to or better than when PPIs were combined. Considering the potent acid-inhibitory effect of tegoprazan, tegoprazan-based therapy can be expected as effective as PPI-based therapy for H. pylori eradication. However, the effectiveness of tegoprazan in regions with high clarithromycin resistance rates (>20%) remains unclear.
Although the recommended first-line regimen was revised according to the increase in antibiotic resistance, a 7-day triple regimen comprising a PPI, amoxicillin, and clarithromycin is still widely prescribed first-line therapeutic option globally, including in Korea.5
We aimed to assess the efficacy and safety of tegoprazan-based triple therapy versus PPI-based triple therapy in H. pylori-positive patients. Subgroup analyses were performed according to the CYP2C19 genotype, the MICs of amoxicillin and clarithromycin, and underlying gastric diseases (i.e., peptic ulcer disease or chronic atrophic gastritis).
MATERIALS AND METHODS
1. Study design
This study was a phase III, randomized, double-blind, multicenter, active-controlled, comparative study for assessing the non-inferiority of tegoprazan-based triple therapy to lansoprazole-based triple therapy in H. pylori-positive patients with chronic atrophic gastritis and/or peptic ulcer diseases (gastric ulcer or duodenal ulcer). The study involved 21 investigators at 18 centers in South Korea. The protocol for this study was approved by the institutional review boards of each institution including Severance Hospital (IRB number: 4-2017-0795). The study was conducted in accordance with the Declaration of Helsinki and the International Council on Harmonization of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice guidelines. The study was registered at ClinicalTrials.gov (NCT03317223; A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy with CJ-12420 in H. Pylori Positive Patients).
2. Study participants
Male or female patients who met all of the following inclusion criteria were eligible to participate in the study: age, 20 to 75 years; living in South Korea; outpatients with complaints of epigastric discomfort; H. pylori positivity; and had been diagnosed with peptic ulcer diseases (i.e., gastric ulcer or duodenal ulcer) and/or chronic atrophic gastritis using upper gastrointestinal endoscopy at screening.
Patients with any of the following conditions were excluded from the study: prior therapy for H. pylori eradication; acute epigastric hemorrhage; acute gastric mucosal lesion; acute duodenal mucosal lesion; had undergone or planned to undergo surgery which might affect gastric acid secretion; Zollinger-Ellison syndrome; gastric acid hypersecretion disorder; gastric outlet obstruction; endoscopic diagnosis of gastric cancer during screening; history of malignancy within the last 5 years; pregnancy; breast-feeding women; history of allergy to any of the study drugs or their related compounds; clinically significant hepatic or renal disease; use of a PPI or H2-receptor antagonist 14 days before screening; or use of bismuth or antibiotics with known efficacy in H. pylori eradication within 28 days before screening. All the participants provided written informed consent before participating in the study.
3. Study protocol
During screening, the baseline characteristics and medical history (including history of H. pylori eradication therapy) of the participants were recorded. Physical examinations, vital sign assessments, clinical laboratory tests, pregnancy tests, and electrocardiography were performed. For diagnosis of H. pylori infection status, 13C-urea breath test (UBT) was mandatory. In addition, at least one among the three tests—stool antigen test, rapid urease test, or biopsy-based culture—was performed before treatment. It was determined as H. pylori-positive when the participant was positive for UBT and at least one of the other tests was positive. Upper gastrointestinal endoscopy was performed to determine the status of underlying diseases, such as gastric or duodenal ulcer or chronic atrophic gastritis. Antimicrobial susceptibility tests were performed on the biopsied gastric mucosal tissues (collected after obtaining consent), which were cultured and analyzed at a designated single center (Department of Microbiology, Hanyang University College of Medicine, Seoul, Korea).
The participants were allocated to the therapy group in a 1:1 ratio using stratified block randomization. If eligible based on assessments for the inclusion/exclusion criteria, the participant was assigned a participant number in the chronological order of enrolment. All randomization information was securely stored and accessible only to authorized personnel.
The participants were instructed to take the following drugs: one tegoprazan 50 mg or lansoprazole 30 mg tablet and one matched placebo capsule; two amoxicillin 500 mg capsules; and one clarithromycin 500 mg tablet. All the drugs including tegoprazan or lansoprazole and antibiotics were administered orally twice a day for 7 days after meals at the same time.
At the end of the treatment period, physical examination, vital sign assessments, and clinical laboratory tests were performed. CYP2C19 genotyping were performed using the blood samples by Green Cross LabCell Corp. Adverse events (AEs), concomitant medications, and treatment compliance were assessed by a well-trained investigator. The participants were followed up and evaluated for H. pylori status after an additional 28 to 56 days, after the end of the treatment (Fig. 1). Because some drugs could affect the accuracy of the UBT, the study participants were not allowed to take any antibiotics, PPIs, or bismuth products within 4 weeks prior to the test.
Fig. 1.
Schematic diagram showing the study design.
TPZ, tegoprazan-based triple therapy; LPZ, lansoprazole-based triple therapy.
H. pylori eradication was determined using 13C-UBTs performed by a central laboratory (Green Cross LabCell Corp., Yongin, Korea). The cutoff value was 2.0%; if the UBT result was ≤2%, it was considered “negative.” The CYP2C19 genotyping and antimicrobial susceptibility tests were performed only for the participants who consented to the tests. The final result of this study will be disseminated to the participants by mail.
1) H. pylori culture and isolation
Two biopsy specimens were obtained from the antrum of the stomach of each patient, stored in a deep freezer below –80℃. The samples were maintained at a temperature of –80℃ to –20℃ during transport to a designated laboratory center, at the Department of Microbiology, Hanyang University College of Medicine. The transportation time of most specimens did not exceed 2 hours. Bacteria were isolated from frozen specimens under microaerophilic conditions (5% O2, 10% CO2, and 85% N2). The specimens were inoculated onto Brucella agar base supplemented with 7% sheep blood, vancomycin (10 mg/mL), trimethoprim (5 mg/mL), amphotericin B (5 mg/mL), and polymyxin B (1.25 U/mL). The plates were incubated at 37℃ under microaerophilic conditions for 5 to 7 days. The isolated bacteria were placed in a Brucella liquid medium containing 15% glycerol and stored in a deep freezer below –80℃.
Suspected H. pylori colonies were subcultured and evaluated based on the colony morphological features; Gram staining; and positive reaction with urease, oxidase, and catalase. Subsequently, H. pylori was identified using polymerase chain reaction for the UreC gene. The primers for H. pylori UreC (GenBank Accession No. M60398.1) were as follows: sense primer, 5′-AAG CTT TTA GGG GTG TTA GGG GTT T-3′ (positions 1293–1317); and antisense primer, 5′-AAG CTT ACT TTC TAA CAC TAA CGC-3′ (positions 1586–1563). The polymerase chain reactions were performed in an automated thermal cycler (2720 Thermal Cycler; Applied Biosystems, Foster City, CA, USA) under the following conditions: 35 cycles each of 1 minute at 94℃, 1 minute at 55℃, and 1 minute at 72℃. The polymerase chain reaction products were assessed using gel electrophoresis (expected amplicon size, 294 bp), for verifying the presence of the UreC gene in the cultured bacteria.
2) MIC analysis
The MICs of amoxicillin (Sigma Chemical Co., St. Louis, MO, USA) and clarithromycin (Sigma Chemical Co.) in the isolates were measured using the serial 2-fold agar dilution method. The reference used for susceptibility testing was chosen based on the recommendations of the Clinical and Laboratory Standards Institute. H. pylori ATCC 43504 was used as the reference strain. The resistance breakpoint for amoxicillin was defined as >0.125 μg/mL, as recommended by the European Committee on Antimicrobial Susceptibility Testing guidelines. The breakpoint for clarithromycin was defined as >0.5 μg/mL, according to Clinical and Laboratory Standards Institute guidelines.
3) Outcome parameters used to assess efficacy
The primary efficacy endpoint was the H. pylori eradication rate determined based on the UBT performed at the central laboratory. The secondary efficacy endpoints were as follows: (1) H. pylori eradication rate according to the MICs of clarithromycin and amoxicillin; (2) H. pylori eradication rate according to the endoscopic underlying disease; and (3) H. pylori eradication rate according to the CYP2C19 genotype.
4) Safety assessment
Safety was evaluated via physical examination, electrocardiography, vital signs, laboratory tests (complete blood count with differential, blood chemistry, blood coagulation tests and urinalysis), and incidence of treatment-emergent adverse events (TEAEs). A TEAE was defined as an AE occurring after the participant received the study drug. TEAEs were categorized based on severity and relativity and compared between the treatment groups. All TEAEs, including AEs, adverse drug reactions, and serious AEs, were coded based on the System Organ Classes and Preferred Terms by using MedDRA and compared between treatment groups.
4. Statistical analyses
The H. pylori eradication rate was assumed as 79.8% for lansoprazole-based triple therapy based on earlier reports15 and 86.0% for tegoprazan-based triple therapy, using the upper limit of the confidence interval (CI). The sample size was determined as 140 participants per treatment group to achieve 95% power to detect the non-inferiority of tegoprazan to lansoprazole with a non-inferiority margin of 10%. The non-inferiority margin was determined according to previous studies.15,16 The sample size was 350 participants with 175 participants per group, considering a 20% dropout rate. Efficacy were primarily assessed in the per-protocol set (PPS) according to Food and Drug Administration;17 Primary endpoint was assessed in an intention-to-treat (ITT), full analysis set (FAS) and PPS, but subgroups were analyzed primarily in the PPS. The PPS was defined as all participants in the FAS after excluding any of the following criteria: (1) withdrawal from the study without participation for the entire duration; (2) incomplete procedures for the primary endpoint; (3) never administered study drug; (4) administered with any contraindicated medication; (5) less than 80% of compliance; (6) performing UBT within 14 days from the last dose of rescue drug (H2-receptor antagonist); and (7) other significant protocol violations. The safety analysis set (SAS) was defined as all participants enrolled in the study who received at least one dose of study treatment and had at least one safety assessment.
Non-inferiority tests were used to compare the primary endpoints. The chi-square test or the Fisher exact test was used to assess the differences between the treatment groups which included age, sex, underlying endoscopic disease, clarithromycin resistance, amoxicillin resistance, and CYP2C19 genotype. The risk factors for H. pylori eradication failure were used for the multivariable logistic regression analysis. Statistical analyses were performed using the SAS software (version 9.3; Windows, SAS Institute, NC, USA). The non-inferiority test was used if the lower limit of the two-sided 95% CI for the difference between the two arms was greater than the non-inferiority margin, –10%. Two-sided p-values <0.05 were considered statistically significant. Subgroup analyses were conducted using the chi-square test or the Fisher exact test.
RESULTS
1. Baseline characteristics
Among the 528 participants who provided written informed consent, 350 eligible participants were randomly allocated to receive triple therapy with tegoprazan (n=175, TPZ) or lansoprazole (n=175, LPZ) (Fig. 2). Three and two patients who either withdrew consent or did not meet the inclusion criteria were excluded from the TPZ and LPZ groups, respectively. All participants who received at least one dose of the study drug were assigned to the set for safety analysis. Therefore, 172 and 173 participants were assigned to the TPZ and LPZ groups, respectively (SAS). The FAS included all the eligible patients based on inclusion and exclusion criteria from the SAS. A total of 321 participants (161 TPZ group and 160 LPZ group) completed the eradication therapy (Fig. 2).
Fig. 2.
CONSORT flow diagram. From the tegoprazan-based triple therapy (TPZ) and lansoprazole-based triple therapy (LPZ) groups, 161 and 160 participants, respectively, completed the eradication therapy.
The primary endpoint was evaluated for the participants in an ITT set, FAS and PPS. Finally, 150 patients each from the TPZ and LPZ groups were included in the efficacy evaluation (PPS) (Fig. 2). The demographic and other baseline characteristics of the TPZ and LPZ groups in the ITT and PPS are summarized (Table 1, Supplementary Table 1). The baseline characteristics were not remarkably different between the treatment groups in both ITT and PPS.
Table 1.
Demographic and Baseline Characteristics (Intention-to-Treat)
| Characteristics | TPZ (n=175) | LPZ (n=175) |
|---|---|---|
| Age, yr | 54.71±11.24 | 53.19±10.88 |
| Sex | ||
| Male | 85 (48.57) | 83 (47.43) |
| Female | 90 (51.43) | 92 (52.57) |
| Height, cm | 164.03±9.32 | 163.31±8.56 |
| Weight, kg | 65.64±11.26 | 64.17±11.95 |
| Smoking | ||
| Yes | 26 (14.86) | 24 (13.71) |
| No | 149 (85.14) | 151 (86.29) |
| Alcohol drinking | ||
| Yes | 57 (32.57) | 76 (43.43) |
| No | 118 (67.43) | 99 (56.57) |
| Underlying gastric diseases | ||
| Peptic ulcer disease | 50 (28.57) | 50 (28.57) |
| Chronic atrophic gastritis | 125 (71.43) | 125 (71.43) |
| CYP2C19 genotype test* | ||
| Extensive/Intermediate metabolizer | 127 (88.81) | 129 (85.43) |
| Poor metabolizer | 16 (11.19) | 22 (14.57) |
| Clarithromycin susceptibility† | ||
| Susceptible or intermediate (MIC ≤0.5 μg/mL) | 27 (72.97) | 26 (66.67) |
| Resistant (MIC >0.5 μg/mL) | 10 (27.03) | 13 (33.33) |
| AMX susceptibility† | ||
| Susceptible or intermediate (MIC ≤0.125 μg/mL) | 29 (78.38) | 28 (71.79) |
| Resistant (MIC >0.125 μg/mL) | 8 (21.62) | 11 (28.21) |
Data are presented as mean±SD or number (%).
TPZ, tegoprazan-based triple therapy; LPZ, lansoprazole-based triple therapy; CYP, cytochrome P450; MIC, minimum inhibitory concentration; AMX, amoxicillin.
*Only the participants who consented to the genetic test were tested; †Gastric mucosa specimens were obtained from only 88 patients; among them, the MIC test was performed for the 76 patients in whose samples Helicobacter pylori culture was successful.
2. Efficacy analyses
The H. pylori eradication rate of each TPZ and LPZ group was 62.86% (110/175) and 60.57% (106/175) in an ITT analysis, 63.53% (108/170) and 61.27% (106/173) in the FAS (non-inferiority test, p=0.009 and p=0.010) (Fig. 3A and B). In the PPS, the eradication rate was 69.33% (104/150) in the TPZ group and 67.33% (101/150) in the LPZ group (Fig. 3C).
Fig. 3.
Helicobacter pylori eradication rates with first-line triple therapy in an intention-to treat (A), full analysis (B), and per-protocol set (C). The p-values for non-inferiority tests are provided.
TPZ, tegoprazan-based triple therapy; LPZ, lansoprazole-based triple therapy. *Statistically significant.
The two-sided 95% CI for the difference in the H. pylori eradication rate between the TPZ and LPZ groups was –8.53 and 12.50, respectively. Therefore, tegoprazan-based triple therapy was noninferior to lansoprazole-based triple therapy as the lower limit of the CI was above the non-inferiority margin of –10% (p=0.013).
Further analyses of H. pylori eradication rates were performed for the following subgroups in the PPS: underlying gastric diseases based on endoscopic findings, age, sex, resistance to clarithromycin or amoxicillin, and CYP2C19 genotype. The eradication rates of participants with peptic ulcers in the TPZ and LPZ groups were 76.19% and 66.67%, respectively. There was no statistically significant difference (p=0.327) (Fig. 4A).
Fig. 4.
Helicobacter pylori eradication rates according to underlying gastric disease (A), MICs of antibiotics (B, C), age (D), and sex (E).
TPZ, tegoprazan-based triple therapy group; LPZ, lansoprazole-based triple therapy group; PUD, peptic ulcer disease; CAG, chronic gastritis; NS, not significant; MIC, minimum inhibitory concentration; CLR, clarithromycin; AMX, amoxicillin.
The H. pylori eradication rate was lower in patients infected with clarithromycin-resistant strains (MIC >0.5 μg/mL) than in those with clarithromycin-susceptible or clarithromycin-intermediate sensitivity strains (MIC ≤0.5 μg/mL), in both regimen groups (Fig. 4B). However, subtype analysis according to the MIC differences of clarithromycin and amoxicillin or according to CYP2C19 polymorphisms showed no significant difference between the two regimens (Fig. 4B and C, Supplementary Tables 2 and 3). The eradication rates did not significantly differ between the two groups when analyzed by age and sex (Fig. 4D and E). Results from subgroup analyses for FAS were not different from those for PPS (Supplementary Fig. 1).
In addition, multivariate logistic regression analysis showed that sex, age, smoking, CYP2C19 genotype, and type of acid blocker did not significantly affect the eradication rate; however, clarithromycin resistance had a significant negative impact (odds ratio, 0.04; 95% CI, 0.01 to 0.19; p<0.001) (Supplementary Table 4).
3. Antimicrobial susceptibility results
Gastric tissue collection for antimicrobial susceptibility testing was performed only for participants who consented to the tissue collection procedure. Gastric mucosal specimens were collected from 88 of 350 participants. Antimicrobial susceptibility test results were obtained for 76 participants; for 12 participants, H. pylori could not be isolated from the specimens (H. pylori culture success rate, 86.3%). The resistance rates to clarithromycin and amoxicillin in this study were 30.3% (23/76) and 25.0% (19/76), respectively.
After excluding eight cases who were not included in the PPS, the antimicrobial susceptibility result was analyzed (Fig. 5). In 19 of the 68 participants (27%), H. pylori showed resistance to clarithromycin. The MIC distributions were as follows: 8 μg/mL (n=3), 16 μg/mL (n=3), 32 μg/mL (n=9), 64 μg/mL (n=2), 128 μg/mL (n=1), and 128 μg/mL or higher (n=1) (Fig. 5A). In the case of amoxicillin, 18 of the 68 participants (26.5%) showed resistance. The MIC profile was as follows: 0.25 μg/mL (n=13), 0.5 μg/mL (n=4), and 1 μg/mL (n=1) (Fig. 5B).
Fig. 5.
Distribution of the minimum inhibitory concentration (MIC) of clarithromycin (A) and amoxicillin (B), determined using the Helicobacter pylori isolates obtained from study participants. The dotted line indicates the break point for each antibiotic. The breakpoints for clarithromycin and amoxicillin were 0.5 μg/mL and 0.125 μg/mL, respectively; however, they are placed a little to the right of the breakpoint, for readability. The majority of isolates (dotted arrow) resistant to clarithromycin had MIC values ranging from 8 to 128 μg/mL.
LPZ, lansoprazole-based triple therapy; TPZ, tegoprazan-based triple therapy.
4. Safety analyses
The overall incidence of TEAEs was 41.86% in the TPZ group compared with 39.31% in the LPZ group (37.79% vs 33.53% for drug-related TEAEs). The incidence of TEAEs, drug-related TEAEs, TEAEs leading to study drug discontinuation, and serious TEAEs were comparable between the treatment groups (Table 2). One participant each in the TPZ and the LPZ groups, who experienced urticaria and diarrhea, respectively, quit the treatment; these participants voluntarily withdrew from the study (Table 2). TEAEs such as diarrhea, dysgeusia, upper abdominal pain, and headache were noted in >2% of the participants (Table 3). The TEAEs did not significantly differ between the tegoprazan-based and lansoprazole-based triple therapies. Two serious TEAEs were reported in patients receiving lansoprazole-based triple therapy. No significant changes were observed between the two groups with respect to the vital signs, or electrocardiogram findings mean laboratory test values including aspartate aminotransferase and alanine aminotransferase. In particular, no TEAE suggesting hepatotoxicity occurred in either group.
Table 2.
Summary of TEAEs for TPZ and LPZ (Safety Analysis Set)
| Variable | TPZ (n=172) | LPZ (n=173) | p-value* | |||
|---|---|---|---|---|---|---|
| Events | No. of subject (%) | Events | No. of subject (%) | |||
| TEAEs | 118 | 72 (41.9) | 108 | 68 (39.3) | 0.629 | |
| Related | 105 | 65 (37.8) | 91 | 58 (33.5) | ||
| Not related | 13 | 10 (5.8) | 17 | 13 (7.5) | ||
| Mild | 109 | 69 (40.1) | 88 | 57 (33.0) | ||
| Moderate | 9 | 5 (2.9) | 18 | 13 (7.5) | ||
| Severe† | 0 | 0 | 2 | 2 (1.2) | ||
| Leading to study drug discontinuation‡ | 1 | 1 (0.6) | 1 | 1 (0.6) | ||
| Serious TEAEs | 0 | 0 | 2 | 2 (1.2) | 0.499 | |
| Related | 0 | 0 | 0 | 0 | ||
| Not related | 0 | 0 | 2 | 2 (1.2) | ||
TEAEs, treatment-emergent adverse events; TPZ, tegoprazan-based triple therapy; LPZ, lansoprazole-based triple therapy.
*Chi-square test or Fisher exact test; †Both cases were not drug related; ‡The symptoms were not severe, but the subjects wanted to withdraw from the study.
Table 3.
TEAEs Occurring in >2% of Subjects in the Treatment Groups
| MedDRA (system organ class)*,† | TPZ (n=172) | LPZ (n=173) |
|---|---|---|
| Gastrointestinal disorders | 46 (26.74) | 44 (25.43) |
| Diarrhea | 31 (18.02) | 25 (14.45) |
| Upper abdominal pain | 11 (6.40) | 2 (1.16) |
| Abdominal distension | 6 (3.49) | 2 (1.16) |
| Dyspepsia | 4 (2.33) | 6 (3.47) |
| Nausea | 4 (2.33) | 3 (1.73) |
| Abdominal discomfort | 0 | 4 (2.31) |
| Constipation | 0 | 4 (2.31) |
| Dry mouth | 0 | 4 (2.31) |
| Gastroesophageal reflux disease | 0 | 4 (2.31) |
| Nervous system disorders | 28 (16.28) | 28 (16.18) |
| Dysgeusia | 20 (11.63) | 18 (10.40) |
| Headache | 9 (5.23) | 6 (3.47) |
| Dizziness | 2 (1.16) | 4 (2.31) |
| Skin and subcutaneous tissue disorders | 4 (2.33) | 1 (0.58) |
| Urticaria | 4 (2.33) | 1 (0.58) |
Data are presented as number (%).
TEAEs, treatment-emergent adverse events; TPZ, tegoprazan-based triple therapy; LPZ, lansoprazole-based triple therapy.
*MedDRA (version 21.1); †Chi-square test or Fisher exact test.
DISCUSSION
To the best of our knowledge, this is the first randomized, double-blind, controlled phase III study for evaluating the efficacy of H. pylori eradication using a triple therapy regimen containing tegoprazan, a novel P-CAB, in H. pylori-infected South Korean participants. The results indicated the non-inferiority of tegoprazan-based first-line triple therapy to lansoprazole-based triple therapy, in terms of H. pylori eradication rate, with a non-inferiority margin of 10%. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in the eradication rate. Both first-line triple therapies were well tolerated with no notable differences.
A recent, randomized, active comparator-controlled phase III study conducted by Murakami et al.16 in Japan showed that the triple therapy including vonoprazan had a markedly higher H. pylori eradication rate than the PPI-based triple therapy (82% vs 40%) in patients infected with clarithromycin-resistant H. pylori strains. The increased eradication rates were partly attributable to the potential synergy between vonoprazan and the antimicrobials used because H. pylori is more susceptible to antimicrobials when its replicative capability is restored at a pH higher than 6. Our previous study on healthy participants showed that treatment with tegoprazan (50 or 100 mg)-based triple therapy enabled significantly higher gastric acid suppression than PPI-based triple therapy.14 However, in this study, triple therapy containing tegoprazan, a new P-CAB, failed to provide a better outcome, unlike that in the vonoprazan-based triple therapy in Japan.16 The tegoprazan-based triple therapy showed non-inferiority, and not superiority, to lansoprazole-based triple therapy in terms of H. pylori eradication. This result was not significantly different from that of the analysis based on susceptibility to clarithromycin or amoxicillin or CYP2C19 gene polymorphism.
The reason why tegoprazan failed to show superiority over a PPI in H. pylori eradication is not clear; however, there are several hypotheses. First, it is possible that the tegoprazan dose used in this study was not sufficient to enhance the effects of clarithromycin and its metabolites. The administration of 100 mg of tegoprazan increases the levels of clarithromycin and its metabolite (14-hydroxy-clarithromycin) by only 1.1 and 1.3 times, respectively.14 The minimal concentration of tegoprazan (as a component of triple therapy) that can elicit an anti-H. pylori effect is 128 μg/mL. This cannot be reached easily in humans, considering that the highest concentration observed in human plasma is 1.4 μg/mL.18 Second, although both vonoprazan and tegoprazan are P-CABs, they differ in their binding sites, half-life, efficacy, and serum gastrin levels. These differences could contribute to the differences in the anti-H. pylori properties of vonoprazan- and tegoprazan-based triple therapy regimens. Third, the potential inhibitory effect on P-glycoprotein and CYP3A4/5 and acid inhibition could increase the concentrations of clarithromycin and its metabolite at the systemic level.19 Another possible cause for the differences between the effects reported for vonoprazan and tegoprazan could be the differences in the characteristics of the study participants rather than that of the drugs. The MIC distribution of clarithromycin- or amoxicillin-resistant H. pylori strains varies across countries. Such regional differences in antimicrobial resistance rates could be a plausible explanation for eradication rates lower than that in the Japanese study.20-22 There is a possibility that in this study, the MIC distributions for clarithromycin- or amoxicillin-resistant H. pylori strains are skewed to the right compared with those reported in the Japanese study on H. pylori eradication with vonoprazan-based triple therapy.16
In another Japanese study,22 MICs ≥16 μg/mL were not obtained. However, the majority of the clarithromycin-resistant H. pylori in this study had MICs >8 μg/mL and some even had an MIC >128 μg/mL (Fig. 5A). There was almost no resistance to amoxicillin in the earlier study;22 however, in this study, many of the isolated H. pylori colonies showed an MIC ≥0.03 mg/mL for amoxicillin; this was used as a breakpoint in the previous Japanese study with vonoprazan.16 The resistance rate to clarithromycin is similar to that previously reported in Korea,21 but the resistance rate to amoxicillin was high, which could be attributed to the low cutoff value of >0.125 μg/mL. Low H. pylori eradication rates (68.4%) with 14-day vonoprazan-based triple therapy was reported in a study in Thailand, where the rate of clarithromycin-resistant strains is high (16%).23 If the clarithromycin resistance increases with the vonoprazan-based triple therapy regimen as second-line therapy, the effectiveness of vonoprazan is reduced.24 Therefore, considering the results from the various studies, the differences are possibly related to the strength of resistance. Future studies on alternative P-CAB-based triple therapies targeting a population with varying antimicrobial MIC profiles are necessary.
Additionally, the subgroups analysis with ulcer-patients revealed that the eradication rate tended to be higher in the tegoprazan group than in the lansoprazole group (76.19% vs 66.67%), although there was no significant difference (p=0.327). TPZ is superior to LPZ in a strong acidic environment; however, further studies are needed to determine whether TPZ is more effective in the ulcer group. In the present study, clarithromycin resistance was the only significant risk factor for eradication failure (Supplementary Table 4).
The current study reported the safety of tegoprazan-based triple therapy. The SAS analysis showed that the TEAE incidence did not significantly differ between the tegoprazan- and lansoprazole-based triple therapy regimens (41.9% [72/172] vs 39.3% [68/173]). The incidence of upper abdominal pain was significantly higher in the tegoprazan group (11 patients) than that in the lansoprazole group (two patients). However, the patients had only mild symptoms and showed spontaneous improvement. In addition, no significant drug-related TEAEs or newly identified safety profiles were observed in the study.
This study has several limitations. The MIC tests were performed only in a part of the study population because many participants refused consent for the mucosa biopsy, which is essential for MIC testing. Therefore, the sub-analysis on antibiotic resistance based on the MIC should be interpreted carefully. However, the MIC distributions and eradication rates were similar to those observed in a Korean nationwide study on 590 adults.25 The strict randomization process enabled a considerably low possibility of an uneven distribution of antibiotic-resistant strains between the two groups.
This randomized, double-blind study provided evidence that tegoprazan-based 7-day triple therapy can be used for first-line H. pylori therapy, similar to the standard PPIs-based 7-day triple therapy. However, simply replacing PPIs with tegoprazan in triple therapies may not be sufficient to manage clarithromycin-resistant H. pylori strains. Analyses according to the MIC values, studies on other tegoprazan-based therapeutic regimens including 14-day triple therapy, high-dose amoxicillin dual therapy or quadruple therapy are warranted to ascertain whether tegoprazan-based therapy is more effective than PPIs-based therapy for H. pylori eradication.
SUPPLEMENTARY MATERIALS
Supplementary materials can be accessed at https://doi.org/10.5009/gnl220055.
ACKNOWLEDGEMENTS
This study was funded in full by HK inno.N Corp., Seoul, South Korea.
The authors would like to thank all the investigators who contributed to this study: Ji Won Lee, Jie Hyeon Kim, Hyun Wook Park, Bong Tae Kim, and Geun Seog Song, who aided in data management and statistical analyses, are employees of HK inno.N Corp., Seoul, South Korea.
Footnotes
CONFLICTS OF INTEREST
This study was funded in full by HK inno.N Corp., Seoul, South Korea. HK inno.N Corp. contributed to the study design, data management, statistical analysis, and approval of publication in co-operation with all the authors. Y.C.L., B.W.K., and J.H.K. are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
AUTHOR CONTRIBUTIONS
Study concept and design: Y.C.L., J.M.K. Data acquisition: all authors. Data analysis and interpretation: all authors. Drafting of the manuscript: Y.J.C. Critical revision of the manuscript for important intellectual content: Y.C.L., J.M.K. Approval of final manuscript: all authors.
REFERENCES
- 1.Jung HK, Kang SJ, Lee YC, et al. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021;15:168–195. doi: 10.5009/gnl20288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789. doi: 10.1056/NEJMoa001999. [DOI] [PubMed] [Google Scholar]
- 3.Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1275. doi: 10.1016/S0140-6736(83)92719-8. [DOI] [PubMed] [Google Scholar]
- 4.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, author. Schistosomes, liver flukes and Helicobacter pyloriLyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. [PMC free article] [PubMed] [Google Scholar]
- 5.Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–1386. doi: 10.1111/jgh.12607. [DOI] [PubMed] [Google Scholar]
- 6.Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht V/Florence Consensus Report. Gut. 66:6–30. doi: 10.1136/gutjnl-2016-312288. [DOI] [PubMed] [Google Scholar]
- 7.Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367. doi: 10.1136/gutjnl-2015-309252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56–S60. doi: 10.1136/gut.43.2008.S56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Xiong M, Bao Y, Xu X, et al. Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides. Proc Natl Acad Sci U S A. 2017;114:12675–12680. doi: 10.1073/pnas.1710408114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–533. doi: 10.1111/apt.13497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364:275–286. doi: 10.1124/jpet.117.244202. [DOI] [PubMed] [Google Scholar]
- 12.Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12–22. doi: 10.1016/j.pharmthera.2016.08.001. [DOI] [PubMed] [Google Scholar]
- 13.Lambrecht N, Munson K, Vagin O, Sachs G. Comparison of covalent with reversible inhibitor binding sites of the gastric H,K-ATPase by site-directed mutagenesis. J Biol Chem. 2000;275:4041–4048. doi: 10.1074/jbc.275.6.4041. [DOI] [PubMed] [Google Scholar]
- 14.Ghim JL, Chin MC, Jung J, et al. Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects. J Clin Pharmacol. 2021;61:913–922. doi: 10.1002/jcph.1805. [DOI] [PubMed] [Google Scholar]
- 15.Nishida T, Tsujii M, Tanimura H, et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol. 2014;20:4362–4369. doi: 10.3748/wjg.v20.i15.4362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446. doi: 10.1136/gutjnl-2015-311304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Food and Drug Administration, Department of Health and Human Services, author. Draft guidance for industry on Helicobacter pylori-associated duodenal ulcer disease in adults: developing drugs for treatment; availability [Internet] Federal Register; Washington DC: c2009. [cited 2022 Mar 25]. Available from: https://www.federalregister.gov/d/E9-23875 . [Google Scholar]
- 18.Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50:751–759. doi: 10.1111/apt.15438. [DOI] [PubMed] [Google Scholar]
- 19.Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409–418. doi: 10.1007/s40262-015-0326-7. [DOI] [PubMed] [Google Scholar]
- 20.Alarcón T, Urruzuno P, Martínez MJ, et al. Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enferm Infecc Microbiol Clin. 2017;35:278–282. doi: 10.1016/j.eimc.2016.02.010. [DOI] [PubMed] [Google Scholar]
- 21.Kim JY, Kim NY, Kim SJ, et al. Regional difference of antibiotic resistance of Helicobacter pylori strains in Korea. Korean J Gastroenterol. 2011;57:221–229. doi: 10.4166/kjg.2011.57.4.221. [DOI] [PubMed] [Google Scholar]
- 22.Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018;17:29. doi: 10.1186/s12941-018-0281-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sanglutong L, Aumpan N, Pornthisarn B, et al. Ineffectiveness of 14-day vonoprazan-based dual therapy and vonoprazan-based triple therapy for Helicobacter pylori eradication in area of high clarithromycin resistance: a prospective randomized study. Gastroenterology. 2020;158:S. doi: 10.1016/S0016-5085(20)32134-X. [DOI] [Google Scholar]
- 24.Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Helicobacter. 2017;22:e12438. doi: 10.1111/hel.12438. [DOI] [PubMed] [Google Scholar]
- 25.Lee JH, Ahn JY, Choi KD, et al. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter. 2019;24:e12592. doi: 10.1111/hel.12592. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.